Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFMO Maintenance for Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
NCT06892678Phase 2Recruiting
- Sponsor
- Montefiore Medical Center
- Start
- Apr 2025
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eflornithine in osteosarcoma (OS) and Ewing sarcoma, sponsored by Montefiore Medical Center. Primary endpoint: Feasibility of Administering DFMO at 2 years. Started Apr 2025; status: recruiting.
02
Drugs
eflornithine
03
Conditions
osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on NCT06892678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892678.